Shanghai Henlius Biotech

OverviewSuggest Edit

Shanghai Henlius Biotech provides clinical-stage biopharmaceutical services. The company focuses on the development, production, and commercialization of mAb (monoclonal antibody) biosimilar drugs, bio-betters, and mAbs. Its products in development cover a variety of therapeutic areas including oncology and autoimmune diseases.

TypePrivate
Founded2009
Websitehenlius.com

Latest Updates

Employees (est.) (Jul 2019)127(+4%)
Cybersecurity ratingCMore

Shanghai Henlius Biotech Financials and Metrics

Summary Metrics

Founding Date

2009

Shanghai Henlius Biotech total Funding

$346 m

Shanghai Henlius Biotech latest funding size

$156 m

Time since last funding

2 years ago

Shanghai Henlius Biotech investors

Shanghai Henlius Biotech's latest funding round in July 2018 was reported to be $156 m. In total, Shanghai Henlius Biotech has raised $346 m
Show all financial metrics

Shanghai Henlius Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Shanghai Henlius Biotech Online and Social Media Presence

Embed Graph

Shanghai Henlius Biotech Frequently Asked Questions

  • When was Shanghai Henlius Biotech founded?

    Shanghai Henlius Biotech was founded in 2009.

  • How many employees does Shanghai Henlius Biotech have?

    Shanghai Henlius Biotech has 127 employees.

  • Who are Shanghai Henlius Biotech competitors?

    Competitors of Shanghai Henlius Biotech include Immunovative Therapies, Achieve Life Sciences and Ayala Pharmaceuticals.